RSV Vaccine for Older Adults: A New Era in Protection

Respiratory syncytial virus (RSV) poses a significant health threat to older adults, often leading to severe illness and hospitalization. For years, there was no vaccine available to protect this vulnerable population. However, recent advancements have led to the development and approval of the first RSV vaccines, marking a turning point in preventative medicine. This article provides an overview of the RSV vaccines for older adults, their efficacy, safety, and what they mean for public health.

Understanding RSV and Its Impact on Older Adults

RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, in older adults, RSV can lead to more serious complications, including pneumonia, bronchitis, and exacerbation of chronic conditions like asthma and heart failure. RSV is one of the major infectious diseases for which there was previously no vaccine or specific treatment available for older adults. GSK highlights the significant burden of RSV in this age group.

The Development of RSV Vaccines

The development of RSV vaccines has been a long-standing challenge. Recent breakthroughs in vaccine design, particularly the leverage of prefusion F protein technology, have paved the way for highly effective candidates. The bivalent RSV prefusion F protein–based vaccine (RSVpreF) has shown promising results in clinical trials. Research published in the New England Journal of Medicine details the efficacy of this vaccine in preventing hospitalization due to RSV.

Efficacy and Safety of RSV Vaccines

Clinical trials have demonstrated a high degree of efficacy for RSV vaccines in older adults. Studies have shown vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above. Positive vaccine efficacy has similarly been observed in participants with comorbidities, who are at increased risk of severe outcomes. GSK’s phase III trial results, published in the New England Journal of Medicine, showed a favorable safety profile.

Current Recommendations and Availability

As of late 2025, RSV vaccines are becoming available for older adults. Regulatory decisions have been made in the US, EU, and other countries, allowing for widespread vaccination. Updated evidence also supports the use of RSV vaccines alongside COVID-19 and influenza vaccines. A recent study in the New England Journal of Medicine highlights the importance of staying up-to-date with all recommended vaccinations.

Looking Ahead

The introduction of RSV vaccines represents a major advancement in protecting older adults from a potentially serious illness. Continued monitoring of vaccine effectiveness and safety will be crucial, as will efforts to increase vaccination rates. The progress made in RSV vaccine design also holds promise for the development of vaccines against other respiratory viruses. Experts recognize a new era in vaccine design based on this research.